The P2X7 purinergic receptor as a molecular target in bipolar disorder

Neuropsychiatria i Neuropsychologia

Volumn 8, Issue 1, 2013, Pages 1-7

  Gubert, Carolina ^a,b   Fries, Gabriel Rodrigo ^a,b   De Aguiar, Bianca Wollenhaupt ^a,b   Rosa, Adriane Ribeiro ^a   Busnello, João Vicente ^a,d   Ribeiro, Luciana ^a,d   Morrone, Fernanda Bueno ^c   Battastini, Ana Maria Oliveira ^b   Kapczinski, Flávio ^a  

^a HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

^b FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^c PONTIFICAL CATHOLIC UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^d UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

Author keywords

Bipolar disorder; Inflammation; Microglia; P2X7R; Purinergic system

Indexed keywords

ADENOSINE RECEPTOR; ALLOPURINOL; G PROTEIN COUPLED RECEPTOR; HALOPERIDOL; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 1BETA; LITHIUM; MOOD STABILIZER; PURINERGIC P2 RECEPTOR; PURINERGIC P2X7 RECEPTOR; PURINERGIC RECEPTOR; TRICYCLIC ANTIDEPRESSANT AGENT; TUMOR NECROSIS FACTOR ALPHA; URIC ACID;

APOPTOSIS; BIPOLAR DISORDER; BRAIN ATROPHY; BRAIN STEM; CELL PROLIFERATION; CEREBELLUM; CYTOLYSIS; DISEASE ASSOCIATION; EXCITOTOXICITY; FRONTAL CORTEX; GENETIC ASSOCIATION; GLIA CELL; HIPPOCAMPUS; HUMAN; MANIA; MICROGLIA; MOLECULARLY TARGETED THERAPY; NERVOUS SYSTEM INFLAMMATION; NEUROMODULATION; NEUROTRANSMISSION; NONHUMAN; NUCLEUS ACCUMBENS; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; THALAMUS; YOUNG MANIA RATING SCALE;

EID: 84879616541     PISSN: 18966764     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (49)

1. Abbracchio MP, Burnstock G. Purinergic signalling: pathophysiological roles. Jpn J Pharmacol 1998; 78: 113-145. (Pubitemid 28508403)
2. Abkevich V, Camp NJ, Hensel CH, et al. Predisposition locus for major depression at chromosome 12q22-12q23.2. Am J Hum Genet 2003; 73: 1271-1281. (Pubitemid 38037421)
3. Akhondzadeh S, Milajerdi MR, Amini H, Tehrani-Doost M. Allopurinol as an adjunct to lithium and haloperidol for treatment of patients with acute mania: a double-blind, randomized, placebo-controlled trial. Bipolar Disord 2006; 8: 485-489. (Pubitemid 44560222)
4. Apolloni S, Montilli C, Finocchi P, Amadio S. Membrane compartments and purinergic signalling: P2x receptors in neurodegenerative and neuroinflammatory events. FEBS J 2009; 276: 354-364.
5. Backlund L, Nikamo P, Hukic DS, et al. Cognitive manic symptoms associated with the P2rx7 gene in bipolar disorder. Bipolar Disord 2011; 13: 500-508.
6. Baroja-Mazo A, Barberà-Cremades M, Pelegrín P. The participation of plasma membrane hemichannels to purinergic signaling. Biochim Biophys Acta 2013; 1828: 79-93.
7. Basso AM, Bratcher NA, Harris RR, et al. Behavioral profile of P2x7 receptor knockout mice in animal models of depression and anxiety: relevance for neuropsychiatric disorders. Behav Brain Res 2009; 198: 83-90.
8. Bayer TA, Buslei R, Havas L, Falkai P. Evidence for activation of microglia in patients with psychiatric illnesses. Neurosci Lett 1999; 271: 126-128. (Pubitemid 29400683)
9. Berk M, Kapczinski F, Andreazza AC, et al. Pathways underlying neuroprogression in bipolar disorder: focus on inflammation, oxidative stress and neurotrophic factors. Neurosci Biobehav Rev 2011; 35: 804-817.
10. Boucher AA, Arnold JC, Hunt GE, et al. Resilience and reduced c-Fos expression in P2x7 receptor knockout mice exposed to repeated forced swim test. Neuroscience 2011; 189: 170-177.
11. Burnstock G, Williams M. P2 purinergic receptors: modulation of cell function and therapeutic potential. J Pharmacol Exp Ther 2000; 295: 862-869.
12. Chakfe Y, Seguin R, Antel JP, et al. ADP and AMP induce interleukin-1beta release from microglial cells through activation of ATP-primed P2x7 receptor channels. J Neurosci 2002; 22: 3061-3069. (Pubitemid 35379195)
13. Chang YC, Kim HW, Rapoport SI, Rao JS. Chronic NMDA administration increases neuroinflammatory markers in rat frontal cortex: cross-talk between excitotoxicity and neuroinflammation. Neurochem Res 2008; 33: 2318-2323.
14. Di Virgilio F. Liaisons dangereuses: P2x(7) and the inflammasome. Trends Pharmacol Sci 2007; 28: 465-472.
15. Di Virgilio F, Ceruti S, Bramanti P, Abbracchio MP. Purinergic signalling in inflammation of the central nervous system. Trends Neurosci 2009; 32: 79-87.
16. Ekdahl CT. Microglial activation - tuning and pruning adult neurogenesis. Front Pharmacol 2012; 3: 41.
17. Ferré S. Adenosine-dopamine interactions in the ventral striatum. Implications for the treatment of schizophrenia. Psychopharmacology (Berl) 1997; 133: 107-120. (Pubitemid 27404740)
18. Fredholm BB, IJzerman AP, Jacobson KA, et al. International union of pharmacology. XXV. Nomenclature and classification of adenosine receptors. Pharmacol Rev 2001; 53: 527-552. (Pubitemid 33136237)
19. Kraeplin E. Manic-Depressive Insanity and Paranoia. Edinburgh 1921.
20. Leboyer M, Soreca I, Scott J, et al. Can bipolar disorder be viewed as a multi-system inflammatory disease? J Affect Disord 2012; 141: 1-10.
21. Lewandowski KE, Cohen BM, Ongur D. Evolution of neuropsychological dysfunction during the course of schizophrenia and bipolar disorder. Psychol Med 2011; 41: 225-241.
22. Lopes LV, Sebastião AM, Ribeiro JA. Adenosine and related drugs in brain diseases: present and future in clinical trials. Curr Top Med Chem 2011; 11: 1087-1101.
23. Lucattelli M, Cicko S, Müller T, et al. P2x7 receptor signaling in the pathogenesis of smoke-induced lung inflammation and emphysema. Am J Respir Cell Mol Biol 2011; 44: 423-429.
24. Mantere O, Soronen P, Uher R, et al. Neuroticism mediates the effect of P2rx7 on outcomes of mood disorders. Depress Anxiety 2012; 29: 816-823.
25. McQuillin A, Bass NJ, Choudhury K, et al. Case-control studies show that a non-conservative amino-acid change from a glutamine to arginine in the P2rx7 purinergic receptor protein is associated with both bipolar- and unipolar-affective disorders. Mol Psychiatry 2009; 14: 614-620.
26. Monif M, Burnstock G, Williams DA. Microglia: proliferation and activation driven by the P2x7 receptor. Int J Biochem Cell Biol 2010; 42: 1753-1756.
27. Morgan JT, Chana G, Pardo CA, et al. Microglial activation and increased microglial density observed in the dorsolateral prefrontal cortex in autism. Biol Psychiatry 2010; 68: 368-376.
28. Moriwaki Y, Yamamoto T, Higashino K. Enzymes involved in purine metabolism - a review of histochemical localization and functional implications. Histol Histopathol 1999; 14: 1321-1340. (Pubitemid 29447472)
29. Munkholm K, Vinberg M, Vedel Kessing L. Cytokines in bipolar disorder: a systematic review and meta-analysis. J Affect Disord 2013; 144: 16-27.
30. Nimmerjahn A, Kirchhoff F, Helmchen F. Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo. Science 2005; 308: 1314-1318. (Pubitemid 40746128)
31. North RA. Molecular physiology of P2x receptors. Physiol Rev 2002; 82: 1013-1067.
32. Pessac B, Godin I, Alliot F. Microglia: origin and development. Bull Acad Natl Med 2001; 185: 337-346; discussion 346-337.
33. Rao JS, Harry GJ, Rapoport SI, et al. Increased excitotoxicity and neuroinflammatory markers in postmortem frontal cortex from bipolar disorder patients. Mol Psychiatry 2010; 15: 384-392.
34. Ribeiro JA, Sebastia~o AM, de Mendonça A. Adenosine receptors in the nervous system: pathophysiological implications. Prog Neurobiol 2002; 68: 377-392. (Pubitemid 36165128)
35. Salvadore G, Viale CI, Luckenbaugh DA, et al. Increased uric acid levels in drug-naïve subjects with bipolar disorder during a first manic episode. Prog Neuropsychopharmacol Biol Psychiatry 2010; 34: 819-821.
36. Saul MC, Gessay GM, Gammie SC. A new mouse model for mania shares genetic correlates with human bipolar disorder. PLoS One 2012; 7: e38128.
37. Skaper SD, Debetto P, Giusti P. P2x(7) receptors in neurological and cardiovascular disorders. Cardiovasc Psychiatry Neurol 2009; 2009: 861324.
38. Skaper SD, Debetto P, Giusti P. The P2x7 purinergic receptor: from physiology to neurological disorders. FASEB J 2010; 24: 337-345.
39. Söderlund J, Olsson SK, Samuelsson M, et al. Elevation of cerebrospinal fluid interleukin-1β in bipolar disorder. J Psychiatry Neurosci 2011; 36: 114-118.
40. Soronen P, Mantere O, Melartin T, et al. P2rx7 gene is associated consistently with mood disorders and predicts clinical outcome in three clinical cohorts. Am J Med Genet B Neuropsychiatr Genet 2011; 156B: 435-447.
41. Stertz L, Magalhães PV, Kapczinski F. Is bipolar disorder an inflammatory condition? The relevance of microglial activation. Curr Opin Psychiatry 2013; 26: 19-26.
42. Stone TW, Ceruti S, Abbracchio MP. Adenosine receptors and neurological disease: neuroprotection and neurodegeneration. Handb Exp Pharmacol 2009; (193): 535-587.
43. Suzuki T, Hide I, Ido K, et al. Production and release of neuroprotective tumor necrosis factor by P2x7 receptor-activated microglia. J Neurosci 2004; 24: 1-7. (Pubitemid 38181664)
44. Tschopp J, Schroder K. Nlrp3 inflammasome activation: the convergence of multiple signalling pathways on ROS production? Nat Rev Immunol 2010; 10: 210-215.
45. Walter L, Dinh T, Stella N. ATP induces a rapid and pronounced increase in 2-arachidonoylglycerol production by astrocytes, a response limited by monoacylglycerol lipase. J Neurosci 2004; 24: 8068-8074. (Pubitemid 39280826)
46. Weisman GA, Camden JM, Peterson TS, et al. P2 receptors for extracellular nucleotides in the central nervous system: role of P2x7 and P2y2 receptor interactions in neuroinflammation. Mol Neurobiol 2012; 46: 96-113.
47. Weitz TM, Town T. Microglia in Alzheimer's disease: it's all about context. Int J Alzheimers Dis 2012; 2012: 314185.
48. Wilot LC, Bernardi A, Frozza RL, et al. Lithium and valproate protect hippocampal slices against ATP-induced cell death. Neurochem Res 2007; 32: 1539-1546. (Pubitemid 47094415)
49. Wilot LC, Da Silva RS, Ferreira OJ, et al. Chronic treatment with lithium increases the ecto-nucleotidase activities in rat hippocampal synatosomes. Neurosci Lett 2004; 368: 167-170. (Pubitemid 39194865) Tecnológico Nível Superior